U.K. agency backs expanding indications for rituximab

rituximab.jpg

Convinced by a steady stream of research, the U.K.'s National Institute for Health and Clinical Excellence (NICE) has chosen to back Rituxan (known in the U.K. as MabThera) as a treatment for people with advanced follicular lymphoma in new draft guidance to be published next month.

NICE, the agency that advises the state-run National Health Service, or NHS, on drugs and therapies that offer a good value for the costs involved, told media outlets in an email that the research behind adding Rituxan to existing chemotherapy regimens leads to longer overall survival rates and a higher quality of life.

This stamp of approval is good news for U.K. patients with indolent non-Hodgkin's lymphomas, particularly those with follicular lymphoma.

Source: Bloomberg

LymphomaInfo Social